88 results about "Mania" patented technology

The present invention is a method for the treatment of mania and / or bipolar disorder comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined.

The invention relates to the technical field of health management and specifically relates to a chronic disease management system based on exercise intervention, diet intervention and mental intervention. The system provided by the invention comprises an intelligent service platform, portable equipment and a mobile terminal, wherein the portable equipment is used to collect information and transmit the information to the intelligent service platform; the intelligent service platform is used to customize personalized exercise prescriptions, diet prescriptions and mental intervention prescriptions; and the mobile terminal is used to inquire various types of information and prescriptions and assess a user's anxiety, depression, fear, mania, pessimism and happiness degrees by questionnaires. By the invention, a closed-loop health management service can be provided for a client; personalized prescriptions can be issued based on comprehensive evaluation of a patient's health conditions, mental conditions, diet conditions and lifestyles, so that the patient can execute a scheme customized for him / her.

Methods and kits for assessing the susceptibility of a patient to antidepressant-induced mania are described. The method involves testing a sample from a patient for the presence of the s variant of the 5HTTLPR polymorphism in the 5HTT gene. The presence of this s variant indicates that the patient is more susceptible to antidepressant-induced mania.

Pyridone-fused azabicyclic compounds of the formulaand their pharmaceutically acceptable salts and prodrugs, wherein R<1>, R<2 >and R<3 >are defined below, intermediates and methods for their preparation. Compositions and methods for using compounds of the formula I in the treatment of neurological and mental disorders related to a decrease in cholinergic function such as nicotine addiction, Huntington's Chorea, tardive dyskinesia, hyperkinesia, mania, dyslexia, schizophrenia, analgesia, attention deficit disorder (ADD), multi-infarct demetia, age related cognitive decline, epilepsy, neurological and mental disorders related to a decrease in cholinergic function, senile dementia of the Alzheimer's type, Parkinson's disease, attention deficit hyperactivity disorder (ADHD), anxiety, obesity, Tourette's Syndrome and ulcerative colitis.

The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

The present invention provides compounds of the general formula (I)wherein X, n and R1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT2a and dopamine D3 receptors, useful in the treatment and / or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

The present invention relates to ether derivatives according to general formula I,and to their pharmaceutically-acceptable salts, which may be used in treating or preventing cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, or psychoses comprising paranoia and delusions.

The present invention provides methods for the diagnosis and treatment of psychiatric disorders. In particular, the present invention provides convergent functional genomics methods for the identification of candidate genes associated with psychiatric disorders such as mania and psychosis, as well as other multi-faceted diseases and syndromes.

The invention discloses an organic acid lithium amino acid salt. An organic acid lithium is one or more of lithium isobutyrate, lithium n-butyrate, lithium lactate, lithium citrate or lithium cholesterol; an amino acid is one of L-proline, valine, lysine or artificially synthesized amino acid; and the organic acid lithium amino acid salt is a salt formed by the organic acid lithium and the amino acid. The invention also discloses a crystal form, a preparation method and application of the salt. The organic acid lithium amino acid salt has a positive curative effect and a prevention effect on repeated attack of mania and depression in bipolar affective disorders, can delay degenerative diseases of a central nervous system to achieve better distribution of the central nervous system, and reduces the clinical dosage of the lithium salt while enhancing the curative effect of the central nervous system diseases, so as to avoid the occurrence of peripheral adverse reaction.

The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.

The present invention provides methods of identifying an increased risk of a dopamine dysregulation disorder in a human subject, including identifying increased risk of dementia, Parkinson's disease, Huntington's, epilepsy, mania, attention deficit disorder, anxiety, dyslexia, schizophrenia, depression, obsessive-compulsive disorders, alcoholism, obesity, addiction disorders, pathological gambling, attention deficit hyperactivity disorder, bipolar disorder, Tourette syndrome, substance dependence, sub stance abuse, substance overdose, and substance-related death.

The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-sero-tonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamaza-pine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, as well as methods to prepare the compositions and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.

The invention discloses an intelligent nursing device for psychiatric nursing, and mainly relates to the field of psychiatric restraint tools. The nursing device comprises a restraint ring, a rotatingring, a restraint rod and an air bag, wherein the restraint ring and the rotating ring are rotationally connected on a circumferential end face; sliding blocks which are in sliding fit in the axial direction of the restraint ring are arranged on the inner wall of the restraint ring; first ball joint seats are arranged on the sliding blocks; second ball joint seats with the same number as the sliding blocks are arrayed on the inner wall of the rotating ring in the circumferential direction; the two ends of the restraint rod are matched with the first ball joint seats and the second ball jointseats respectively; the air bag is fixed to an inner ring of the restraint ring; inflation and deflation of the air bag are achieved through a medical air source; a pulse detection piece is fixed to the air bag; the pulse detection piece is in signal connection with a stepping motor; and the stepping motor is triggered to be started by setting a lower limit threshold value of the heart rate. The nursing device has the beneficial effects that the locking is timely, constraint is fast, the four-limb behavior of a patient in a mania state is fast responded and constrained, limitation is reliableand safe, and the injury to the patient is greatly reduced.